Swiss biotechnology company Araris Biotech completed its sale to Taiho Pharmaceutical. In connection with the deal BGPartner advised Araris on all Swiss legal matters, while Baker McKenzie represented the company with regard to all Swiss
Tags :Oliver Gnehm
BGPartner has advised OrbiMed and Novo Holdings on Swiss legal matters related to the USD 200 million Series A financing of Windward Bio Group, a Swiss-based clinical-stage drug development company, advised by Homburger. The financing round
Swiss biotech company Alentis Therapeutics has successfully closed a $181.4 million oversubscribed Series D financing round, supported by a syndicate of top-tier biotech investors. The financing will support the company to develop a deep pipeline of
Memo Therapeutics, a late-stage biotech firm specializing in top-tier therapeutic antibodies, disclosed the successful conclusion of its CHF 25 million Series C funding round. This milestone was spearheaded by Pureos Bioventures, with strong participation from Memo
GOLDBEK Holding, a fast growing and innovative German greeting card publishing company, has acquired 100% of ABC Kunst- und Glückwunschkartenverlag (its legal name is A. Boss & Co), a privately owned Swiss market leader in
Samsung Ventures has made a strategic investment in Araris Biotech. The investment corporation, that was established to promote the development of new technologies, has invested in the company in an independent deal ahead of its
Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system disorders, successfully closed an oversubscribed Series B financing round, raising CHF 103 mio (approx. USD 112 mio). The round was co-led by the European healthcare focused
SynAct Pharma, a Swedish listed biotechnology company has acquired all shares of TXP Pharma, a privately owned Swiss biotech company, researching and developing pharmaceutical drugs for the treatment of autoimmune and inflammatory diseases. Through this
BGPartner has advised Araris Biotech in a CHF 24 million financing round, involving the two co-lead investors 4BIO Capital and Pureos Bioventures. Araris Biotech, a company pioneering antibody-drug conjugate (ADC) linker technology, intends to use the
Lalique Group has signed an agreement to acquire the long-established silk label Fabric Frontline. Founded in Zurich over 40 years ago, the company gained international recognition with its high-quality silk collections that combine quality awareness, individual
